Ask AI
ProCE Banner Series

What’s Next in SCLC: Expert Perspectives on Practice-Changing Updates From 2025 Global Congresses

Enhance your understanding of the efficacy and safety of current and emerging agents used to treat SCLC across the disease continuum based on findings from the 2025 ASCO, ESMO, and WCLC meetings through an expert-written ClinicalThought commentary and certified on-demand webcast with accompanying downloadable slides.

Who Should Attend

This activity is intended for oncologists and other healthcare professionals caring for patients with small-cell lung cancer.

Topics

Lung Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge and clinical competence by equipping them with the most recent evidence to support the application of emerging treatment strategies, biomarker insights, and safety considerations into the personalized care of patients with small cell lung cancer across all stages and lines of therapy.

Target Audience
This activity is intended for oncologists and other healthcare professionals caring for patients with small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Summarize key efficacy and safety findings from the 2025 ASCO, ESMO, and WCLC meetings that inform first-line and maintenance treatment decisions for patients with limited-stage and extensive-stage SCLC

  • Evaluate the role of immunotherapy in the evolving management of limited-stage and extensive-stage SCLC, including new evidence supporting consolidation or maintenance strategies

  • Analyze recent data on lurbinectedin, DLL3-targeted bispecific antibodies, and antibody–drug conjugates to support optimal sequencing strategies for patients with relapsed/refractory SCLC

  • Interpret emerging biomarker evidence, such as SLFN11 and DLL3 expression, to determine its potential role in treatment personalization for patients with SCLC

  • Apply clinical best practices for mitigating immune-related and agent-specific adverse events associated with novel agents in the SCLC treatment landscape

  • Integrate new evidence into individualized treatment plans by considering performance status, comorbidities, and quality-of-life considerations across lines of therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by educational funding provided by Amgen and Boehringer Ingelheim Pharmaceuticals, Inc.

Amgen

Boehringer Ingelheim Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191